Correlation of covid-19 and Guillain-Barré syndrome: A Mechanistic Perspective

Sharma, V.K.; Chhabra, Tarun; Singh, Thakur Gurjeet

doi:10.1016/j.obmed.2023.100493

Cited by 2 publications

(1 citation statement)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…White matter damage was seen in 57% of 4342 hospitalized COVID-19 patients [26]. Reports indicated effect of COVID-19 infection in triggering demyelinating diseases, such as multiple sclerosis [27], acute disseminated encephalomyelitis [28], Guillain Barré syndrome [29,30]. The neurotoxic action of the virus is mediated by binding to angiotensin-converting enzyme-2 (ACE2) receptors or indirectly by inducing cytokine storm leading to disruption of the blood-brain barrier, immunological mediation, increasing blood coagulation and as a trigger for autoimmune-mediated demyelinating injuries in the CNS [31,32].…”

mentioning

confidence: 99%

Demyelination in Patients with Post-COVID Depression

Khodanovich,

Svetlik,

Kamaeva

et al. 2023

Preprint

View full text Add to dashboard Cite

Depression is one of the most severe sequelae of COVID-19, with major depressive disorder often characterized by disruption in white matter (WM) connectivity , stemming from changes in brain myelination. This study aimed to quantitatively assess brain myelination in clinically diagnosed post-COVID depression using recently proposed MRI method, macromolecular proton fraction (MPF) mapping. The study involved 63 recovered COVID-19 patients (52 mild, 11 moderate, 2 severe) at 13.5±10.0 months post-recovery, with matched controls without prior COVID-19 history (n=19). A post-COVID depression group (PCD, n=25) was identified based on psychiatric diagnosis, while a comparison group (noPCD, n=38) included participants with neurological COVID-19 complications, excluding clinical depression. Fast MPF mapping revealed extensive demyelination in PCD patients, particularly in juxtacortical WM (predominantly occipital lobe and medial surface), WM tracts (inferior fronto-occipital fasciculus (IFOF), posterior thalamic radiation, external capsule, sagittal stratum, tapetum), and grey matter (GM) structures (hippocampus, putamen, globus pallidus, and amygdala). The noPCD group also displayed notable demyelination but with less magnitude and propagation. Multiple regression analysis highlighted IFOF demyelination as the primary predictor of PCD presence and severity according to Hamilton scores. The number of post-COVID symptoms was a significant predictor of PCD presence while the number acute of symptoms was a significant predictor of PCD severity. This study, for the first time, reveals extensive demyelination in numerous WM and GM structures in PCD, outlining IFOF demyelination as a key biomarker.

show abstract

mentioning

confidence: 99%

Demyelination in Patients with Post-COVID Depression

Khodanovich,

Svetlik,

Kamaeva

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Demyelination in Patients with POST-COVID Depression

Khodanovich,

Svetlik,

Kamaeva

et al. 2024

JCM

View full text Add to dashboard Cite

Background: Depression is one of the most severe sequelae of COVID-19, with major depressive disorder often characterized by disruption in white matter (WM) connectivity stemming from changes in brain myelination. This study aimed to quantitatively assess brain myelination in clinically diagnosed post-COVID depression (PCD) using the recently proposed MRI method, macromolecular proton fraction (MPF) mapping. Methods: The study involved 63 recovered COVID-19 patients (52 mild, 11 moderate, and 2 severe) at 13.5 ± 10.0 months post-recovery, with matched controls without prior COVID-19 history (n = 19). A post-COVID depression group (PCD, n = 25) was identified based on psychiatric diagnosis, while a comparison group (noPCD, n = 38) included participants with neurological COVID-19 complications, excluding clinical depression. Results: Fast MPF mapping revealed extensive demyelination in PCD patients, particularly in juxtacortical WM (predominantly occipital lobe and medial surface), WM tracts (inferior fronto-occipital fasciculus (IFOF), posterior thalamic radiation, external capsule, sagittal stratum, tapetum), and grey matter (GM) structures (hippocampus, putamen, globus pallidus, and amygdala). The noPCD group also displayed notable demyelination, but with less magnitude and propagation. Multiple regression analysis highlighted IFOF demyelination as the primary predictor of Hamilton scores, PCD presence, and severity. The number of post-COVID symptoms was a significant predictor of PCD presence, while the number of acute symptoms was a significant predictor of PCD severity. Conclusions: This study, for the first time, reveals extensive demyelination in numerous WM and GM structures in PCD, outlining IFOF demyelination as a key biomarker.

show abstract

Correlation of covid-19 and Guillain-Barré syndrome: A Mechanistic Perspective

Cited by 2 publications

References 103 publications

Demyelination in Patients with Post-COVID Depression

Demyelination in Patients with Post-COVID Depression

Demyelination in Patients with POST-COVID Depression

Contact Info

Product

Resources

About